INCY Stock Chart & Stats
$2036.00
$30.00(1.50%)
At close: 4:00 PM EDT
$2036.00
$30.00(1.50%)
Day’s Range― - ―
52-Week Range$1,301.04 - $2,373.80
Previous CloseN/A
Volume9.71K
Average Volume (3M)332.00
Market Cap
$459.32B
Enterprise Value$19.11K
Total Cash (Recent Filing)$4.54B
Total Debt (Recent Filing)$32.68M
Price to Earnings (P/E)16.0
Beta0.01
Next Earnings
Nov 03, 2026EPS Estimate
-37.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.13
Shares Outstanding202,697,740
10 Day Avg. Volume998
30 Day Avg. Volume332
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,221.48Price Target Upside9.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)85.13
Revenue Forecast (FY)$102.33B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Minimal DebtMinimal debt (debt-to-equity ~0.5%) and an expanded equity base give Incyte substantial financial flexibility to fund launches, sustain multi-year R&D, and pursue M&A without adding leverage. Low structural indebtedness reduces refinancing and solvency risk over the medium term.
Strong Cash Generation And High MarginsVery high TTM gross and operating margins plus robust operating cash flow (~$2.0B) and FCF (~$1.9B) create durable internal funding for pipeline development and launches. Strong cash conversion supports strategic optionality and reduces reliance on external financing across several years.
Pipeline Diversification And Strategic M&AThe Vega acquisition (VGA039 Phase 3) plus multiple late‑stage programs, regulatory submissions and recent Opzelura EU approval materially broaden Incyte’s commercial footprint. These structural moves diversify revenue away from Jakafi and build durable hematology and dermatology franchises.
Bears Say
Revenue Concentration In JakafiJakafi remains the single largest revenue driver, implying material concentration risk. Until new launches and acquired assets scale, adverse competitive, reimbursement, or safety developments affecting Jakafi would materially reduce revenue predictability and cash flow resilience.
Sustained Elevated R&D And Operating SpendOngoing heavy investment in late‑stage trials and launch readiness improves long‑term prospects but structurally raises cash burn and pressures GAAP profitability. Success of multiple programs is required to justify sustained spend; execution shortfalls would strain margins and cash deployment plans.
Safety Signal And Trial/approval Timing Risk (734)Reported pneumonitis cases and an administrative hold introduce regulatory scrutiny and execution risk for the 734 program. Safety-driven delays or additional monitoring obligations can extend timelines, increase costs, and affect eventual label/market access for a material oncology candidate.
Incyte News
INCY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $1301.04 and its highest was $2373.80 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is $459.32B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is Nov 03, 2026 which is in 95 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Jul 28, 2026. The company reported $53.891 earnings per share for the quarter, beating the consensus estimate of $38.299 by $15.592.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is -37.92.
How many shares outstanding does Incyte have?
Incyte has 202,697,740 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of $53.891 in its last earnings report, beating expectations of $38.299. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in MX:INCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,221.48 (9.11% Upside)
$2,221.48 (9.11% Upside)
Blogger Sentiment
Bullish
MX:INCY Sentiment 76%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $144.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 96%
Bearish news 4%
Bearish news 4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Company Description
Incyte
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and substantial pipeline/regulatory progress: double‑digit top‑line growth (Q1 revenue +21%, net sales +20%), outsized core ex‑Jakafi growth (+63% YoY), multiple late‑stage programs and regulatory acceptances (povorcitinib, 989 EOP meeting, 734 Phase III) and leadership hires to support launches. Offsetting risks include elevated R&D/operating spend, a small safety review and administrative hold related to pneumonitis in the 734 program, and continued revenue concentration in Jakafi. On balance the positives—robust revenue growth, core business acceleration, and clear late‑stage catalysts—outweigh the lowlights, though execution and safety monitoring remain important near‑term considerations.View all MX:INCY earnings summariesINCY Revenue Breakdown
84.69% Product revenues, net
12.39% Product royalty revenues
2.92% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$2,221.48
▲(9.11% Upside)